Literature DB >> 21116298

Testicular germ cell tumors: pathogenesis, diagnosis and treatment.

Christian Winter1, Peter Albers.   

Abstract

Testicular germ cell tumors represent the most common solid malignancy of young men aged 15-40 years. Histopathologically, testicular germ cell tumors are divided into two major groups: pure seminoma and nonseminoma. The pathogenesis of testicular germ cell tumors remains unknown; however, cryptorchidism is the main risk factor, and molecular studies have shown strong evidence of an association between genetic alterations and testicular germ cell tumors. In cases of suspicion for testicular germ cell tumor, a surgical exploration with orchiectomy is obligatory. After completion of diagnostic procedures, levels of serum tumor markers and the clinical stage based on the International Union Against Cancer tumor-node-metastasis classification should be defined. Patients with early-stage testicular germ cell tumors are treated by individualized risk stratification within a multidisciplinary approach. The individual management (surveillance, chemotherapy or radiotherapy) has to be balanced according to clinical features and the risk of short-term and long-term toxic effects. Treatment for metastatic tumors is based on risk stratification according to International Germ Cell Cancer Collaborative Group classification and is performed with cisplatin-based chemotherapy and residual tumor resection in cases of residual tumor lesion. High-dose chemotherapy represents a curative option for patients with second or subsequent relapses.

Entities:  

Mesh:

Year:  2010        PMID: 21116298     DOI: 10.1038/nrendo.2010.196

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  75 in total

1.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

Authors:  K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.

Authors:  H von der Maase; M Rørth; S Walbom-Jørgensen; B L Sørensen; I S Christophersen; T Hald; G K Jacobsen; J G Berthelsen; N E Skakkebaek
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-29

4.  The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.

Authors:  Janine Nuver; Andries J Smit; Bruce H R Wolffenbuttel; Wim J Sluiter; Harald J Hoekstra; Dirk T Sleijfer; Jourik A Gietema
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

5.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

6.  High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors.

Authors:  A Lorch; A Neubauer; M Hackenthal; A Dieing; J T Hartmann; O Rick; C Bokemeyer; J Beyer
Journal:  Ann Oncol       Date:  2009-10-11       Impact factor: 32.976

7.  Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study.

Authors:  Y C Bayens; P A Helle; W L Van Putten; S P Mali
Journal:  Radiother Oncol       Date:  1992-10       Impact factor: 6.280

8.  Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.

Authors:  Danielle M Doyle; Lawrence H Einhorn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-01       Impact factor: 7.038

Review 9.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

10.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Authors:  Anja Lorch; Christian Kollmannsberger; Joerg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

View more
  41 in total

1.  Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.

Authors:  F Aranda; N Bloy; J Pesquet; B Petit; K Chaba; A Sauvat; O Kepp; N Khadra; D Enot; C Pfirschke; M Pittet; L Zitvogel; G Kroemer; L Senovilla
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

2.  In vitro study on shRNA-mediated reduction of testis developmental related gene 1 expression and its effects on the proliferation, invasion and apoptosis of NTERA-2 cells.

Authors:  Y U Gan; Jianfu Yang; Yong Wang; Zhengyu Tan; Xianzhen Jiang; Yuxin Tang
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

3.  Testicular Choriocarcinoma Metastasizing to the Small Bowel Causing Intussusception: Case Report.

Authors:  Shaimaa Elzamly; Alireza Torabi; Osvaldo Padilla
Journal:  J Gastrointest Cancer       Date:  2019-12

4.  The role of spermatogenesis-associated protein 6 in testicular germ cell tumors.

Authors:  Shiwei Huo; Wenyan Du; Peng Shi; Yuexiu Si; Shengtian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship.

Authors:  Lisa C Richardson; Antonio J Neri; Eric Tai; Jeffrey D Glenn
Journal:  Urol Oncol       Date:  2011-11-27       Impact factor: 3.498

6.  Metabolic vulnerability of cisplatin-resistant cancers.

Authors:  Florine Obrist; Judith Michels; Sylvere Durand; Alexis Chery; Jonathan Pol; Sarah Levesque; Adrien Joseph; Valentina Astesana; Federico Pietrocola; Gen Sheng Wu; Maria Castedo; Guido Kroemer
Journal:  EMBO J       Date:  2018-06-06       Impact factor: 11.598

Review 7.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Authors:  Judith Michels; Ilio Vitale; Laura Senovilla; David P Enot; Pauline Garcia; Delphine Lissa; Ken A Olaussen; Catherine Brenner; Jean-Charles Soria; Maria Castedo; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

9.  Vitamin B6 metabolism influences the intracellular accumulation of cisplatin.

Authors:  Lorenzo Galluzzi; Sabrina Marsili; Ilio Vitale; Laura Senovilla; Judith Michels; Pauline Garcia; Erika Vacchelli; Etienne Chatelut; Maria Castedo; Guido Kroemer
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

10.  Prognostic value of LIPC in non-small cell lung carcinoma.

Authors:  Lorenzo Galluzzi; Aicha Goubar; Ken André Olaussen; Ilio Vitale; Laura Senovilla; Judith Michels; Angélique Robin; Nicolas Dorvault; Benjamin Besse; Pierre Validire; Pierre Fouret; Carmen Behrens; Ignacio Ivan Wistuba; Jean-Charles Soria; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-01-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.